1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Microbix Biosystems Inc.

Microbix Biosystems Inc.

MBX.TO
Microbix Biosystems Inc.CA flagToronto Stock Exchange
0.30
CAD
- -
- -
41.25MMarket Cap
Microbix Biosystems Inc.
MBX.TO
(Toronto Stock Exchange)

Recent

price

0.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.13
0.11
0.11
0.11
0.12
0.11
0.11
0.12
0.13
0.14
0.1
0.16
0.14
0.12
0.18
0.13
0.11
Revenue per Share
-0.05
-0.05
-0.04
- -
- -
0.01
0.01
-0.04
-0.09
- -
-0.06
0.03
0.01
- -
0.03
-0.02
-0.04
Basic EPS, GAAP
-0.04
-0.02
-0.03
- -
-0.07
-0.05
-0.01
- -
-0.02
- -
-0.01
0.01
0.01
-0.02
0.02
-0.01
-0.04
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.43
-0.43
-0.01
-0.01
0.04
0.09
0.09
0.05
-0.02
-0.02
-0.06
0.04
0.1
0.09
0.11
0.11
0.08
Book Value per Share
0.03
0.01
0.02
0.03
0.08
0.1
0.11
0.1
0.06
0.06
0.05
0.15
0.17
0.15
0.17
0.17
0.16
Tangible Book Value per Share
49
55
62
67
69
81
85
85
96
97
105
115
135
138
138
139
139
Basic Weighted Avg Shares
6
6
7
8
8
9
10
10
13
13
11
19
19
17
25
19
15
Sales/Revenue/Turnover
-25.54
-24.82
-25.24
9.85
15.68
12.3
8.82
-5.64
0.87
8.27
-4.98
26.01
13.68
-16.57
15.35
-8.48
-33.4
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
1
1
2
2
2
Depreciation Expense
-3
-3
-2
- -
- -
1
1
-4
-9
- -
-6
3
2
- -
4
-2
-6
Net Income, GAAP
- -
- -
- -
99.18
64.47
- -
- -
- -
- -
26.93
- -
- -
4.14
- -
4.1
- -
- -
Effective Tax Rate (%)
-39.28
-41.2
-35.82
0.02
2.01
6.92
7.86
-37.11
-68.91
0.24
-59.17
17.39
9.38
-0.24
13.86
-12.08
-38.62
Profit Margin (%)
1
1
- -
1
2
2
- -
- -
2
2
2
14
20
18
21
21
18
Working Capital
6
6
5
5
5
6
5
5
5
4
5
5
6
6
6
7
6
LT Debt
6
5
5
6
10
14
15
15
10
11
7
19
25
25
28
28
25
Total Equity
- -
- -
- -
0.06
3.5
- -
- -
- -
- -
4.75
- -
24.75
8.77
- -
11.33
- -
- -
Return on Invested Capital (%)
- -
- -
- -
0.15
6.92
- -
- -
- -
- -
16.71
- -
78.51
16.36
- -
21.77
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
12.34
10.01
-61.84
- -
- -
- -
- -
19.88
-0.31
25.67
-14.93
-37.97
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'26
Mar'26
ST Debt
- -
- -
1
LT Borrowings
5
5
5
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
140
139
138
Market Capitalization
37
32
32

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'26
Mar'26
Total Current Assets
24
23
22
Cash, Cash Equivalents & STI
12
9
8
Accounts Receivable, Net
2
4
3
Inventories
9
9
10
Total Current Liabilities
3
3
4
Payables & Accruals
2
2
2
ST Debt
- -
- -
1
Deferred Revenue
1
1
1

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.05%
45.32%
-1.8%
Free Cash Flow
-44.61%
-143.81%
-135.95%
Net Income, GAAP
-2,964.48%
-1,895.66%
-163.8%
Sales/Revenue/Turnover
11.56%
18.56%
-26.81%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8
6
5
6
25
2025
6
5
3
4
19
2026
4
3
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
0.03
2025
0.01
- -
-0.01
- -
-0.02
2026
-0.01
-0.01
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Celltrion Healthcare Co., Ltd. (091990.KQ)
Omega Therapeutics, Inc. (OMGA)
Cardio Diagnostics Holdings, Inc. (CDIOW)
Biomind Labs Inc. (BMNDF)
Taiwan Bio Therapeutics Co., Ltd (6892.TWO)
Ayala Pharmaceuticals, Inc. (ADXS)
Business
Microbix Biosystems Inc. develops and commercializes proprietary biological and technological solutions for the global diagnostics industry, including infectious disease antigens, quality assessment products (QAPs), viral transport medium, and custom vial filling services; it also advances Kinlytic urokinase, a biologic thrombolytic drug for treating blood clots. The company, founded in 1988 and headquartered in Mississauga, Ontario, Canada, manufactures critical test ingredients such as purified native viral, bacterial, and parasitic antigens covering respiratory pathogens (e.g., SARS-CoV-2, RSV, Influenza A/B, Adenovirus), ToRCH infections (Toxoplasma, Rubella, CMV, HSV), STIs (Chlamydia trachomatis, HSV 1/2), childhood diseases (Measles, Mumps), Dengue types 1-4, and HPV high-risk types; its QAPs portfolio offers external quality controls in liquid, swab, and ONBOARDx formats for respiratory panels, HPV, STIs, genital ulcers, vaginal infections, and gastrointestinal pathogens like C. difficile and Giardia, emulating patient samples for immunoassay, PCR, and POCT validation; DxTM viral transport medium supports specimen collection for COVID-19 and other pathogens in Canada, complemented by aseptic vial filling at scales up to 60,000 vials daily. Microbix operates across North America, Europe, Australia, and internationally, serving over 100 diagnostic manufacturers, labs, and accreditation bodies with CE-marked, FDA-registered, and TGA-approved products shipped to all continents. Recent developments include a November 2025 partnership with SEKISUI Diagnostics to supply REDxFLOQ QAPs for COVID/Flu A/B point-of-care assays on the Metrix platform; the commercial launch of QUANTDx characterized reference materials; supply agreements with Bulgaria's NCIPD for pathogen seedstocks and expanded collaborations with EMQN for genetic-test EQA programs on Clopidogrel metabolism and antibiotic-induced hearing loss; advancements in Kinlytic urokinase drug production via Sequel Pharma's CDMO agreement; Q3 fiscal 2025 results release showing year-to-date Antigens growth amid QAPs challenges; and facility expansions hosting Ontario government officials to enhance manufacturing capacity.